{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:06:52Z","timestamp":1744880812427},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,27]]},"DOI":"10.7759\/cureus.61150","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:03:51Z","timestamp":1716800631000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Study of Emphysematous Cystitis in a Non-diabetic Patient Following Empagliflozin Use: An Uncommon Presentation"],"prefix":"10.7759","author":[{"given":"Nicolette","family":"Busuttil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Galea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3081","article-title":"Endocrinopathies in Aicardi Gouti\u00e8res syndrome - a descriptive case series","volume":"8","author":"Worth C","year":"2020","unstructured":"Worth C, Briggs TA, Padidela R, Balmer E, Skae M. Endocrinopathies in Aicardi Gouti\u00e8res syndrome - a descriptive case series. Clin Case Rep. 2020, 8:2181-5. 10.1002\/ccr3.3081","journal-title":"Clin Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06930.x","article-title":"Emphysematous cystitis: a review of 135 cases","volume":"100","author":"Thomas AA","year":"2007","unstructured":"Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007, 100:17-20. 10.1111\/j.1464-410X.2007.06930.x","journal-title":"BJU Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2020.05.020","article-title":"Osteochondroses of the bilateral metacarpal heads: Dieterich disease. A case report with review of the literature","volume":"67","author":"Ahuja K","year":"2020","unstructured":"Ahuja K, Gandhi D, Hernandez-Delima FJ, Sharma P, Gupta N, Kier R. Osteochondroses of the bilateral metacarpal heads: Dieterich disease. A case report with review of the literature. Clin Imaging. 2020, 67:7-10. 10.1016\/j.clinimag.2020.05.020","journal-title":"Clin Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2023.102321","article-title":"A nontraditional presentation and treatment for emphysematous cystitis","volume":"46","author":"Becker B","year":"2023","unstructured":"Becker B, George A, Owen R. A nontraditional presentation and treatment for emphysematous cystitis. Urol Case Rep. 2023, 46:102321. 10.1016\/j.eucr.2023.102321","journal-title":"Urol Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.04.002","article-title":"Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin","volume":"8","author":"Brock GM","year":"2022","unstructured":"Brock GM, Lane SM, Roosevelt TS. Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin. AACE Clin Case Rep. 2022, 8:163-5. 10.1016\/j.aace.2022.04.002","journal-title":"AACE Clin Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1121","article-title":"Emphysematous cystitis: a review of the literature","volume":"53","author":"Amano M","year":"2014","unstructured":"Amano M, Shimizu T. Emphysematous cystitis: a review of the literature. Intern Med. 2014, 53:79-82. 10.2169\/internalmedicine.53.1121","journal-title":"Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230715","article-title":"Emphysematous cystitis: diagnosed only if suspected","volume":"12","author":"Rajaian S","year":"2019","unstructured":"Rajaian S, Murugavaithianathan P, Krishnamurthy K, Murugasen L. Emphysematous cystitis: diagnosed only if suspected. BMJ Case Rep. 2019, 12:230715. 10.1136\/bcr-2019-230715","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020318","article-title":"Scoring systems to evaluate the mortality risk of patients with emphysematous cystitis: a retrospective observational study","volume":"13","author":"Chen YH","year":"2023","unstructured":"Chen YH, Hsieh MS, Hu SY, Huang SC, Tsai CA, Tsai YC. Scoring systems to evaluate the mortality risk of patients with emphysematous cystitis: a retrospective observational study. J Pers Med. 2023, 13:318. 10.3390\/jpm13020318","journal-title":"J Pers Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"McMurray JJ","year":"2020","unstructured":"McMurray JJ, Solomon SD. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020, 396:819-29. 10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright EM","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011, 91:733-94. 10.1152\/physrev.00055.2009","journal-title":"Physiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini E","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al.. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014, 124:499-508. 10.1172\/JCI72227","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi A","year":"2021","unstructured":"Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021, 26:623-42. 10.1007\/s10741-020-10038-w","journal-title":"Heart Fail Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings S","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014, 103:373-81. 10.1016\/j.diabres.2013.12.052","journal-title":"Diabetes Res Clin Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6803","article-title":"Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: a case report","volume":"11","author":"Hazique M","year":"2023","unstructured":"Hazique M, Surana A, Sinha M, Anand A. Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: a case report. Clin Case Rep. 2023, 11:e6803. 10.1002\/ccr3.6803","journal-title":"Clin Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9120059","article-title":"The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study","volume":"9","author":"Uitrakul S","year":"2022","unstructured":"Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines (Basel). 2022, 9:59. 10.3390\/medicines9120059","journal-title":"Medicines (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115863","article-title":"Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects","volume":"22","author":"Palmiero G","year":"2021","unstructured":"Palmiero G, Cesaro A, Vetrano E, et al.. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021, 22:5863. 10.3390\/ijms22115863","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz170","article-title":"The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?","volume":"13","author":"Sarafidis PA","year":"2020","unstructured":"Sarafidis PA, Ortiz A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. Clin Kidney J. 2020, 13:24-6. 10.1093\/ckj\/sfz170","journal-title":"Clin Kidney J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.01.029","article-title":"Sunlight damage to cellular DNA: Focus on oxidatively generated lesions","volume":"107","author":"Schuch AP","year":"2017","unstructured":"Schuch AP, Moreno NC, Schuch NJ, Menck CF, Garcia CC. Sunlight damage to cellular DNA: Focus on oxidatively generated lesions. Free Radic Biol Med. 2017, 107:110-24. 10.1016\/j.freeradbiomed.2017.01.029","journal-title":"Free Radic Biol Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger RH","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021, 11:263-76. 10.21037\/cdt-20-302","journal-title":"Cardiovasc Diagn Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/218185-a-case-study-of-emphysematous-cystitis-in-a-non-diabetic-patient-following-empagliflozin-use-an-uncommon-presentation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:03:54Z","timestamp":1716800634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/218185-a-case-study-of-emphysematous-cystitis-in-a-non-diabetic-patient-following-empagliflozin-use-an-uncommon-presentation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.61150","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}